Abstract
This document represents the official position of the American Association of Clinical Endocrinologists and the American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.
MeSH terms
-
Algorithms*
-
Blood Glucose / metabolism
-
Blood Pressure
-
Consensus
-
Diabetes Mellitus, Type 2 / metabolism
-
Diabetes Mellitus, Type 2 / physiopathology
-
Diabetes Mellitus, Type 2 / therapy*
-
Humans
-
Hypoglycemic Agents / therapeutic use
-
Insulin / therapeutic use
-
Lipid Metabolism / drug effects
-
Obesity / complications
-
Obesity / metabolism
-
Obesity / physiopathology
-
Obesity / therapy
-
Prediabetic State / metabolism
-
Prediabetic State / pathology
-
Prediabetic State / physiopathology
-
Prediabetic State / therapy
-
United States
Substances
-
Blood Glucose
-
Hypoglycemic Agents
-
Insulin